Avante Raises $30 Million to Expand Its Benefits AI Platform

By Olivia Hart

Avante said it raised $30 million in a Series A round led by Frist Cressey Ventures, lifting total funding to $40 million. Sorenson Capital, Hearst Ventures, Morgan Stanley Next Level Fund and existing investor FUSE joined the round. Avante’s announcement disclosed no valuation or other investment terms.

What will the $30 million fund?

Avante will use the capital to expand internationally and further develop its always-on network of AI agents. The agents target vendor management, renewals, plan analysis, employee support and other recurring benefits processes.

Avante recently launched Ava Agents in beta. The announcement gave no production-deployment figures, pricing or general-availability date, leaving the product’s scale unproven.

How will Ava Agents fit into benefits work?

Avante says Ava Agents can analyze vendor contracts against claims data, review benefits documents for errors or inconsistencies, and track deadlines. The system returns completed work for benefits teams to review, which keeps a human check inside the workflow.

Avante also offers employee-facing tools for personalized guidance on health and other benefit plans. The company says employees can use that guidance throughout the year.

Rohan D’Souza, CEO and co-founder of Avante, said: “Benefits teams are responsible for one of the largest and most consequential investments their companies make, yet they’re still operating with outdated information, archaic spreadsheets, and technology built for another era.” The announcement did not quantify productivity gains or cost savings from the agents.

Senator Bill Frist, M.D., co-founder and managing partner of Frist Cressey Ventures, said: “Avante is harnessing AI to make that system easier to navigate, so employees get better care and employers get relief from costs that keep climbing.” The statement links deployment to better care and employer cost relief, but Avante disclosed no measured savings from its platform.

Avante presents Ava Agents as an assistant to benefits professionals, not an autonomous decision maker. Its stated workflow still depends on teams to review completed work.

What does the customer traction show?

Avante said it had grown to more than 70 customer accounts within 18 months of launch. It also reported bookings nearly five times higher year over year, while every customer eligible for renewal had renewed. The announcement did not define bookings or disclose revenue, renewal-cohort size or average contract value.

Avante says its platform supports more than 385,000 employees and family members. Named customers include Samsung Semiconductor, Real Chemistry, Zscaler and News Corp. Avante also established partnerships with benefits advisors Gallagher, OneDigital, Segal Benz, Howden and USI Insurance Services.

At Real Chemistry, 83% of the company’s U.S. workforce engaged with Avante. Olga Reupert, SVP Total Rewards, HR Global Operations and Enablement at Real Chemistry, said: “With 83% of our U.S. workforce engaging with Avante, employees have on-demand, trusted benefits guidance at their fingertips.” The disclosure establishes participation breadth, but it does not state how often employees used the service.

After implementing Avante, Samsung Semiconductor reported that 66% more employees and dependents identified and used available mental health resources. The 66% figure is a relative increase, not a 66-percentage-point gain, and the announcement did not provide the starting participation level. It also did not isolate other causes, leaving Avante’s causal contribution unproven.

Why does 2027 cost pressure matter?

Avante linked the funding to a projected median 9.2% increase in healthcare costs for 2027 among large employers. The median increase equals 9.2 cents on every current dollar of healthcare spending. The announcement did not identify the survey or employer group behind the projection.

The cost backdrop strengthens the commercial case for benefits software. It does not prove that Avante reduces total costs, because the company disclosed no customer savings figure.

What should investors and buyers watch?

International expansion and Ava Agents’ move beyond beta will test whether Avante can scale. The next disclosures should include production deployments, renewal economics and measured cost or time savings, none of which appears in the current announcement.

Avante also needs to turn its more than 70 accounts and bookings nearly five times higher year over year into recurring revenue. The next checkpoint is whether beta agents produce repeatable savings while Avante sustains customer renewals as healthcare costs rise in 2027.